Chemoradiotherapy combined with immunotherapy in stage III non-small cell lung cancer: a systematic review and meta-analysis of efficacy and safety outcomes

Conclusions Prolonging the duration of immunotherapy consolidation increases survival benefits in patients with stage III NSCLC without causing higher side effects. Older patients, due to high incidence of pneumonia and low immunotherapy completion rate, have less survival benefit.PMID:37903484 | DOI:10.1159/000534376

Source: Oncology - October 30, 2023 Category: Cancer & Oncology Authors: Yang Li Guodong Deng Ning Liang Pingping Hu Yan Zhang Lili Qiao Yingying Zhang Jian Xie Hui Luo Fei Wang Fangjie Chen Fengjun Liu Deguo Xu Jiandong Zhang Source Type: research